Clinical trials
Angioimmunoblastic T-cell Lymphoma clinical trials
Below are recruiting angioimmunoblastic t-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 45 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06561048RecruitingPhase 3
Soquelitinib vs standard care for relapsed or refractory T-cell lymphoma
This trial compares a new drug, soquelitinib, with standard treatments for peripheral T-cell lymphoma that has come back or not responded to previous therapy. It may help people who have had one to three prior treatments and are looking for a new option.
Duarte, CaliforniaAges 18 years+ - NCT06160843RecruitingPhase 2
Pembrolizumab and olaparib for relapsed peripheral T-cell lymphoma
This trial tests whether combining two targeted drugs, pembrolizumab and olaparib, can help people with peripheral T-cell lymphoma that has come back or not responded to previous treatment. The goal is to find a new option for this type of cancer.
SingaporeAges 21–99 - NCT06508463RecruitingPhase 1
Viral therapy for peripheral T-cell lymphoma
This study tests an experimental virus therapy given through a vein for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The virus is designed to infect and destroy cancer cells. Some patients may also receive another drug called cemiplimab as part of a combination group.
Scottsdale, ArizonaAges 18 years+ - NCT06393738RecruitingPhase 1
ARV-393 for relapsed or refractory non-Hodgkin lymphoma
This study tests a new oral medication (ARV-393) for people with certain types of non-Hodgkin lymphoma that have returned or not responded to previous treatments. The drug is designed to target a protein inside cancer cells to make them stop growing and die.
New Haven, ConnecticutAges 18 years+ - NCT05976997RecruitingPhase 2
Test duvelisib plus chidamide for newly diagnosed PTCL
This trial studies whether the combination of duvelisib and chidamide can treat newly diagnosed peripheral T-cell lymphoma (PTCL). Because it is a single-arm study, everyone gets the treatment, and the team monitors response and safety.
Wuhan, HubeiAges 18–70 - NCT05996185RecruitingPhase 2
Study of mogamulizumab plus chemotherapy for T-cell lymphoma
This trial is testing a drug called mogamulizumab combined with standard chemotherapy (DA-EPOCH or CHOEP) for people with aggressive T-cell lymphoma. It aims to see if the combination is safe and works better than chemotherapy alone.
New Haven, ConnecticutAges 18 years+ - NCT05978141Recruiting
T-cell lymphoma registry study
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
Duarte, CaliforniaAges Any age - NCT05833724RecruitingPhase 2
Chidamide for relapsed or resistant peripheral T-cell lymphoma
This trial tests chidamide (a targeted medicine that affects how cells manage gene activity) in people whose peripheral T-cell lymphoma has come back or did not respond to treatment. It may help shrink measurable tumors and control the disease after prior therapies.
Kaohsiung CityAges 20–75 - NCT05313243RecruitingPhase 2
Pembrolizumab plus brentuximab for relapsed T-cell lymphoma
This Phase 2 study tests pembrolizumab together with brentuximab for people whose T-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. It may help shrink the lymphoma and improve long-term control by boosting the immune system and targeting a protein called CD30.
New Haven, ConnecticutAges 18 years+ - NCT05010005RecruitingPhase 1
Testing ruxolitinib plus duvelisib for relapsed T-cell lymphoma
This Phase 1 study tests how safe and effective ruxolitinib plus duvelisib are in adults with certain types of mature T-cell lymphomas. You may be considered if your lymphoma has come back or worsened despite prior treatment, and the study checks whether this pill combination can help control the disease.
Miami, FloridaAges 18 years+ - NCT04803201RecruitingPhase 2
Adding new drugs to usual treatment for peripheral T-cell lymphoma
This trial tests whether adding one of two experimental drugs to the standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma, a rare blood cancer. It aims to see if the combination is safe and effective.
Little Rock, ArkansasAges 18 years+ - NCT04234048RecruitingPhase 1
ST-001 trial for stubborn T-cell lymphoma that came back
This Phase 1 trial tests ST-001, an experimental treatment, for T-cell lymphomas that have returned or did not respond to prior therapy. It aims to find a safe dose and see whether it can shrink or control the lymphoma.
Scottsdale, ArizonaAges 18 years+ - NCT03719105RecruitingEarly Phase 1
Chemo plus immunotherapy with donor stem cell transplant for NK lymphoma
This early-phase study tests a combination treatment—chemo, immunotherapy, and a donor stem cell transplant—for certain aggressive NK/T-cell lymphomas. It may help patients who have advanced-stage disease by trying to improve long-term control of the cancer.
Birmingham, AlabamaAges 1–31 - NCT03081910RecruitingPhase 1
CAR T cells made from your own cells to treat CD5 tumors
This early-phase trial tests a type of immune-cell therapy (CAR T cells) made using T cells with a CD5-targeting “zipper” to treat certain relapsed T-cell cancers. The goal is to see if the treatment can help shrink or clear the cancer, especially enough to move toward a stem cell transplant plan.
Houston, TexasAges Up to 75 years - NCT03017820RecruitingPhase 1
Vaccine plus immune drugs for relapsed blood cancers
This early-phase trial tests a personalized-style vaccine (called VSV-hIFNβ-NIS) given alone or with other cancer-fighting medicines, including drugs that help the immune system attack. It is designed for people with certain relapsed or hard-to-treat multiple myeloma, acute myeloid leukemia, or lymphomas, to see if the treatment can shrink tumors and improve outcomes.
Scottsdale, ArizonaAges 18 years+ - NCT06739265RecruitingPhase 1/Phase 2
Golidocitinib plus CHOP for new T-cell lymphoma
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
BeijingAges 18–70 - NCT07234162RecruitingPhase 3
Study comparing golidocitinib to standard therapy for relapsed T-cell lymphoma
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
Hefei, AnhuiAges 18 years+ - NCT06420089RecruitingPhase 1
CAR T cells for T-cell lymphoma
This trial tests a new CAR T-cell treatment for T-cell lymphoma that has come back or hasn't responded to standard treatments. The treatment is designed to target cancer cells that have a protein called CD5 on their surface.
New York, New YorkAges 18 years+ - NCT06630091RecruitingPhase 2
Golidocitinib for newly diagnosed peripheral T-cell lymphoma
This study tests a new pill called golidocitinib for people newly diagnosed with certain types of peripheral T-cell lymphoma who have not been treated before. The goal is to see if it is safe and effective in shrinking or controlling the lymphoma.
Houston, TexasAges 18 years+ - NCT03125642RecruitingPhase 2
Auto stem cell transplant for lymphoma after chemo
This Phase 2 study tests an auto (self) stem cell transplant for people with certain types of non-Hodgkin lymphoma or Hodgkin lymphoma who respond to chemotherapy (they are “chemo-sensitive”). It may help some patients get a deeper or longer remission by resetting the bone marrow after high-dose treatment.
Minneapolis, MinnesotaAges Up to 75 years - NCT06909474RecruitingPhase 1
CD5-targeted CAR-NK therapy for relapsed T-cell blood cancers
This trial tests a new therapy using your own immune cells (NK cells) engineered to find and kill cancer cells that carry the CD5 protein. It is for people with T-cell acute lymphoblastic leukemia or certain T-cell lymphomas that have not responded to treatment or have returned.
Wuhan, HubeiAges 18–75
Hear when a new Angioimmunoblastic T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for angioimmunoblastic t-cell lymphoma?
- Yes. Clin2 currently lists 45 recruiting angioimmunoblastic t-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a angioimmunoblastic t-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a angioimmunoblastic t-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.